Allon Therapeutics, Inc. reported audited earnings results for the year ended December 31, 2011. For the year, the company reported a net loss of $12,774,995 or $0.15 per share, compared to a net loss of $16,084,481 or $0.21 per share for the year ended December 31, 2010, representing a decrease in net loss of $3,309,486. The company earned interest revenue of $6,662 during the year compared to $23,750 for the same period in 2010. Reduced interest earnings resulted from lower average cash balances and lower interest rates during 2011 compared to 2010.